Cargando…

Immuno-Expression of Endoglin and Smooth Muscle Actin in the Vessels of Brain Metastases. Is There a Rational for Anti-Angiogenic Therapy?

Despite ongoing clinical trials, the efficacy of anti-angiogenic drugs for the treatment of brain metastases (BM) is still questionable. The lower response rate to anti-angiogenic therapy in the presence of BM than in metastatic disease involving other sites suggests that BM may be insensitive to th...

Descripción completa

Detalles Bibliográficos
Autores principales: Barresi, Valeria, Branca, Giovanni, Caffo, Maria, Caltabiano, Rosario, Ieni, Antonio, Vitarelli, Enrica, Lanzafame, Salvatore, Tuccari, Giovanni
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Molecular Diversity Preservation International (MDPI) 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4013588/
https://www.ncbi.nlm.nih.gov/pubmed/24699047
http://dx.doi.org/10.3390/ijms15045663
_version_ 1782315079186776064
author Barresi, Valeria
Branca, Giovanni
Caffo, Maria
Caltabiano, Rosario
Ieni, Antonio
Vitarelli, Enrica
Lanzafame, Salvatore
Tuccari, Giovanni
author_facet Barresi, Valeria
Branca, Giovanni
Caffo, Maria
Caltabiano, Rosario
Ieni, Antonio
Vitarelli, Enrica
Lanzafame, Salvatore
Tuccari, Giovanni
author_sort Barresi, Valeria
collection PubMed
description Despite ongoing clinical trials, the efficacy of anti-angiogenic drugs for the treatment of brain metastases (BM) is still questionable. The lower response rate to anti-angiogenic therapy in the presence of BM than in metastatic disease involving other sites suggests that BM may be insensitive to these drugs, although the biological reasons underlining this phenomenon are still to be clarified. With the aim of assessing whether the targets of anti-angiogenic therapies are actually present in BM, in the present study, we analyzed the microvessel density (MVD), a measure of neo-angiogenesis, and the vascular phenotype (mature vs. immature) in the tumor tissue of a series of BM derived from different primary tumors. By using immunohistochemistry against endoglin, a specific marker for newly formed vessels, we found that neo-angiogenesis widely varies in BM depending on the site of the primary tumor, as well as on its histotype. According to our results, BM from lung cancer displayed the highest MVD counts, while those from renal carcinoma had the lowest. Then, among BM from lung cancer, those from large cell and adenocarcinoma histotypes had significantly higher MVD counts than those originating from squamous cell carcinoma (p = 0.0043; p = 0.0063). Of note, MVD counts were inversely correlated with the maturation index of the endoglin-stained vessels, reflected by the coverage of smooth muscle actin (SMA) positive pericytes (r = −0.693; p < 0.0001). Accordingly, all the endoglin-positive vessels in BM from pulmonary squamous cell carcinoma and renal carcinoma, displayed a mature phenotype, while vessels with an immature phenotype were found in highly vascularized BM from pulmonary large cell and adenocarcinoma. The low MVD and mature phenotype observed in BM from some primary tumors may account for their low sensitivity to anti-angiogenic therapies. Although our findings need to be validated in correlative studies with a clinical response, this should be taken into account in therapeutic protocols in order to avoid the adverse effects of useless therapies.
format Online
Article
Text
id pubmed-4013588
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Molecular Diversity Preservation International (MDPI)
record_format MEDLINE/PubMed
spelling pubmed-40135882014-05-08 Immuno-Expression of Endoglin and Smooth Muscle Actin in the Vessels of Brain Metastases. Is There a Rational for Anti-Angiogenic Therapy? Barresi, Valeria Branca, Giovanni Caffo, Maria Caltabiano, Rosario Ieni, Antonio Vitarelli, Enrica Lanzafame, Salvatore Tuccari, Giovanni Int J Mol Sci Article Despite ongoing clinical trials, the efficacy of anti-angiogenic drugs for the treatment of brain metastases (BM) is still questionable. The lower response rate to anti-angiogenic therapy in the presence of BM than in metastatic disease involving other sites suggests that BM may be insensitive to these drugs, although the biological reasons underlining this phenomenon are still to be clarified. With the aim of assessing whether the targets of anti-angiogenic therapies are actually present in BM, in the present study, we analyzed the microvessel density (MVD), a measure of neo-angiogenesis, and the vascular phenotype (mature vs. immature) in the tumor tissue of a series of BM derived from different primary tumors. By using immunohistochemistry against endoglin, a specific marker for newly formed vessels, we found that neo-angiogenesis widely varies in BM depending on the site of the primary tumor, as well as on its histotype. According to our results, BM from lung cancer displayed the highest MVD counts, while those from renal carcinoma had the lowest. Then, among BM from lung cancer, those from large cell and adenocarcinoma histotypes had significantly higher MVD counts than those originating from squamous cell carcinoma (p = 0.0043; p = 0.0063). Of note, MVD counts were inversely correlated with the maturation index of the endoglin-stained vessels, reflected by the coverage of smooth muscle actin (SMA) positive pericytes (r = −0.693; p < 0.0001). Accordingly, all the endoglin-positive vessels in BM from pulmonary squamous cell carcinoma and renal carcinoma, displayed a mature phenotype, while vessels with an immature phenotype were found in highly vascularized BM from pulmonary large cell and adenocarcinoma. The low MVD and mature phenotype observed in BM from some primary tumors may account for their low sensitivity to anti-angiogenic therapies. Although our findings need to be validated in correlative studies with a clinical response, this should be taken into account in therapeutic protocols in order to avoid the adverse effects of useless therapies. Molecular Diversity Preservation International (MDPI) 2014-04-02 /pmc/articles/PMC4013588/ /pubmed/24699047 http://dx.doi.org/10.3390/ijms15045663 Text en © 2014 by the authors; licensee MDPI, Basel, Switzerland http://creativecommons.org/licenses/by/3.0/ This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/).
spellingShingle Article
Barresi, Valeria
Branca, Giovanni
Caffo, Maria
Caltabiano, Rosario
Ieni, Antonio
Vitarelli, Enrica
Lanzafame, Salvatore
Tuccari, Giovanni
Immuno-Expression of Endoglin and Smooth Muscle Actin in the Vessels of Brain Metastases. Is There a Rational for Anti-Angiogenic Therapy?
title Immuno-Expression of Endoglin and Smooth Muscle Actin in the Vessels of Brain Metastases. Is There a Rational for Anti-Angiogenic Therapy?
title_full Immuno-Expression of Endoglin and Smooth Muscle Actin in the Vessels of Brain Metastases. Is There a Rational for Anti-Angiogenic Therapy?
title_fullStr Immuno-Expression of Endoglin and Smooth Muscle Actin in the Vessels of Brain Metastases. Is There a Rational for Anti-Angiogenic Therapy?
title_full_unstemmed Immuno-Expression of Endoglin and Smooth Muscle Actin in the Vessels of Brain Metastases. Is There a Rational for Anti-Angiogenic Therapy?
title_short Immuno-Expression of Endoglin and Smooth Muscle Actin in the Vessels of Brain Metastases. Is There a Rational for Anti-Angiogenic Therapy?
title_sort immuno-expression of endoglin and smooth muscle actin in the vessels of brain metastases. is there a rational for anti-angiogenic therapy?
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4013588/
https://www.ncbi.nlm.nih.gov/pubmed/24699047
http://dx.doi.org/10.3390/ijms15045663
work_keys_str_mv AT barresivaleria immunoexpressionofendoglinandsmoothmuscleactininthevesselsofbrainmetastasesistherearationalforantiangiogenictherapy
AT brancagiovanni immunoexpressionofendoglinandsmoothmuscleactininthevesselsofbrainmetastasesistherearationalforantiangiogenictherapy
AT caffomaria immunoexpressionofendoglinandsmoothmuscleactininthevesselsofbrainmetastasesistherearationalforantiangiogenictherapy
AT caltabianorosario immunoexpressionofendoglinandsmoothmuscleactininthevesselsofbrainmetastasesistherearationalforantiangiogenictherapy
AT ieniantonio immunoexpressionofendoglinandsmoothmuscleactininthevesselsofbrainmetastasesistherearationalforantiangiogenictherapy
AT vitarellienrica immunoexpressionofendoglinandsmoothmuscleactininthevesselsofbrainmetastasesistherearationalforantiangiogenictherapy
AT lanzafamesalvatore immunoexpressionofendoglinandsmoothmuscleactininthevesselsofbrainmetastasesistherearationalforantiangiogenictherapy
AT tuccarigiovanni immunoexpressionofendoglinandsmoothmuscleactininthevesselsofbrainmetastasesistherearationalforantiangiogenictherapy